Little Green Pharma Ltd.

As of March 31, 2026, Little Green Pharma Ltd. carries a market capitalization of 29.67M, placing it among publicly traded companies globally. Its enterprise value stands at 32.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Little Green Pharma Ltd.'s next confirmed earnings release is scheduled for November 19, 2026.

As of March 31, 2026, Little Green Pharma Ltd. has 305.86M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.70, and the price-to-book ratio stands at 0.36.

As of March 31, 2026, Little Green Pharma Ltd. trades at an EV/EBITDA multiple of 12.53 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 32.94M versus a market cap of 29.67M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Little Green Pharma Ltd. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.65, indicating elevated leverage, while an interest coverage ratio of 5.78 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Little Green Pharma Ltd. posted a negative return on equity (ROE) of -1.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.48, reflecting losses generated across the asset base. Inventory turnover of 0.89 indicates how many times Little Green Pharma Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Little Green Pharma Ltd. recorded an income tax benefit of -136,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.54M and -1.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Little Green Pharma Ltd.'s stock has declined approximately 54.81% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.09.

Over the twelve months ended March 31, 2026, Little Green Pharma Ltd. generated 42.43M in revenue and converted that into -1.41M in net income, yielding earnings per share of 0.00. EBITDA reached 2.63M, while operating income came in at 2.12M.

As of March 31, 2026, Little Green Pharma Ltd. holds 1.42M in cash and equivalents against 4.69M in total debt, resulting in a net debt position of 1.93M. Total book value stands at 83.03M, with working capital of 17.45M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Little Green Pharma Ltd. posted a gross margin of 71.05, reflecting its pricing power and cost economics. The operating margin of 5.00 and net profit margin of -3.32 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Total shareholder yield is negative at -0.08, meaning Little Green Pharma Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Little Green Pharma Ltd. has an Altman Z-Score of 1.97, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.